BRIEF-Bio-Rad Reports Q2 2021 Financial Results · 4d ago
Bio-Rad, 10x Genomics settle genomics patent war
Rivals Bio-Rad Laboratories Inc and 10x Genomics Inc have settled their multi-front battle over microfluidic genetic analysis technology, 10x announced Tuesday.
Reuters · 6d ago
BRIEF-Bio-Rad And 10X Genomics Announce Settlement To Resolve Multiple Litigations · 07/27 16:32
BRIEF-10X Genomics Inc Says Entered Into A Global Settlement And Cross-License Agreement With Bio-Rad Laboratories, Inc · 07/27 11:44
BRIEF-10X Genomics Signs Global Patent Cross License Agreement With Bio-Rad · 07/27 10:36
Bio-Rad, Harvard settle DNA analysis patent dispute with French company
Bio-Rad Laboratories has settled its patent infringement claims against French biotech company Stilla Technologies three days after the start of a trial in Boston federal court, according to a court filing.
Reuters · 07/08 21:26
BRIEF-Bio-Rad Announces Partnership With Seegene For Molecular Diagnostic Testing Products · 06/30 21:04
Fed Circ affirms mixed ITC ruling in 10x and Bio-Rad's patent fight
The U.S. Court of Appeals for the Federal Circuit affirmed an International Trade Commission ruling Friday that some genetic-analysis products imported by 10x Genomics Inc infringe rival Bio-Rad Laboratories Inc's patents.
Reuters · 05/28 22:29
Federal Circuit affirms Bio-Rad infringed rival 10x Genomics' patents
The U.S. Court of Appeals for the Federal Circuit on Thursday upheld a ruling by the International Trade Commission that the importation and sale of Bio-Rad Laboratories Inc genetic-analysis products infringes patents owned by rival 10x Genomics Inc.
Reuters · 04/29 22:25
BRIEF-Bio Rad Laboratories Reports Q1 Non-GAAP Earnings Per Share Of $5.21 · 04/29 20:46
Fitch Assigns First-Time IDR of 'BBB' to STERIS plc; Outlook Stable · 03/17 12:36
Fitch Rates Illumina's Senior Unsecured Notes 'BBB' · 03/16 13:09
Fitch Rates Illumina's First-Time IDR 'BBB'; Outlook Stable · 03/08 21:43
Fitch Rates Agilent's Senior Unsecured Notes 'BBB+' · 03/03 14:03
Fitch Upgrades Thermo Fisher's Long-Term IDR to 'BBB+'; Outlook Stable · 03/01 21:23
BRIEF-Bio-Rad Reports Fourth-Quarter And Full-Year 2020 Financial Results · 02/11 22:31
BRIEF-Bio Rad Laboratories Says Initiated Restructuring Plan In Furtherance Of Ongoing Program To Improve Operating Performance · 02/04 11:24
Renalytix AI Looks For U.S. Public Capital In IPO Filing
Seeking Alpha - Article · 06/29/2020 20:54
New GERM ETF focuses on biotech for infectious diseases
Seeking Alpha - Article · 06/18/2020 14:13
IPO Update: Genetron Holdings Files Proposed IPO Terms
Seeking Alpha - Article · 06/16/2020 17:12
Webull provides a variety of real-time BIO-B stock news. You can receive the latest news about BIO RAD LABORATO through multiple platforms. This information may help you make smarter investment decisions.
About BIO-B
Bio-Rad Laboratories, Inc. manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate chemical and biological materials and to identify, analyze and purify their components. The Company operates through two segments: Life Science and Clinical Diagnostics. Life Science segment markets and develops, manufactures and markets approximately 6,000 reagents, apparatus and laboratory instruments. Its products are used in research techniques, biopharmaceutical production processes and food testing regimes. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market.